| Bioactivity | YC-001 is an inverse agonist and antagonist of rod opsin. YC-001 reversibly binds rod opsin and stabilizes the rod opsin structure. YC-001 protects mice from bright light-induced retinal degeneration. YC-001 has the potential for the research of retinal degeneration[1]. | ||||||||||||
| Invitro | YC-001 (0-100 µM) shows a potency activity of 8.7 µM and an efficacy at 150–310%[1].YC-001 (0.5, 1, 5, 10, 20, 40 µM) improves the glycosylation profile of P23H opsin mutant[1].YC-001 (0,-1.5 µM) reversibly binds rod opsin with EC50 OF 0.98 µM[1].YC-001 (0.313, 0.625, 1.25, 2.5, 5, 10, 20, 80 µM) increases in cAMP level in a dose-dependent manner in NIH3T3 cells[1]. Western Blot Analysis[1] Cell Line: | ||||||||||||
| Name | YC-001 | ||||||||||||
| CAS | 748778-73-6 | ||||||||||||
| Formula | C12H7ClO2S2 | ||||||||||||
| Molar Mass | 282.77 | ||||||||||||
| Transport | Room temperature in continental US; may vary elsewhere. | ||||||||||||
| Storage |
|